基于因果推理的信息理论方法来评估连续结果作为基于因果推理的二元真实终点的替代品:应用于疫苗评估
Ariel Alonso Abad1, Fenny Ong2, Florian Stijven1
1I-BioStat, KU Leuven, Leuven, Belgium.
Statistics in medicine
|January 2, 2024
概括
这项研究引入了一种新的方法,用于验证连续结果作为二进制终点的替代品,使用因果推理. 该方法详细介绍在"代孕R"包中,增强了临床试验分析.
科学领域:
- 生物统计学 生物统计学
- 因果推理因果推理
- 临床试验方法论 临床试验方法论
背景情况:
- 替代终点在临床试验中对于效率至关重要.
- 验证连续结果作为二进制终点的替代品仍然具有挑战性.
- 现有的方法可能无法完全捕捉替代品和真实终点之间的复杂关系.
研究的目的:
- 提出和验证一种新的方法来评估因果关联范式内的二元真终点连续结果的代孕.
- 引入一个信息理论定义的代孕和一个新的指标,个人因果关系.
- 为实施拟议的方法提供一个实际的工具 (R包).
主要方法:
- 开发了一种基于信息理论对代孕的定义的两步方法.
- 提出了一个新的模型,用于替代品和真实终点的潜在结果的联合分布.
- 通过敏感性分析解决了识别问题,并引入了个人因果关联指标.
主要成果:
- 提出的方法有效地评估了作为替代品的连续结果的有效性.
- 敏感性分析成功地处理了联合分销模式中的识别问题.
- 个人因果关系指标为代孕提供了一个新的衡量标准.
- 通过理论分析,模拟和真实世界的流感疫苗试验来证明该方法的实用性.
结论:
- 提出的因果关联框架为验证连续代用终点提供了一个强大的方法.
- 个人因果关系指标推动了临床研究中代孕的评估.
- R包"替代品"有助于在实践中应用这种方法,改善临床试验的设计和解释.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Causality in Epidemiology
421
Causality or causation is a fundamental concept in epidemiology, vital for understanding the relationships between various factors and health outcomes. Despite its importance, there's no single, universally accepted definition of causality within the discipline. Drawing from a systematic review, causality in epidemiology encompasses several definitions, including production, necessary and sufficient, sufficient-component, counterfactual, and probabilistic models. Each has its strengths and...
421
Kaplan-Meier Approach
148
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
148
Assumptions of Survival Analysis
133
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
133
Censoring Survival Data
97
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
97
Comparing the Survival Analysis of Two or More Groups
195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195


